Novartis AG ADR (NVS)vsProgyny Inc (PGNY)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
PGNY
Progyny Inc
$18.58
+0.87%
HEALTHCARE · Cap: $1.51B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4290% more annual revenue ($56.58B vs $1.29B). NVS leads profitability with a 23.9% profit margin vs 4.5%. NVS trades at a lower P/E of 21.2x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PGNY
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+69.5%
Fair Value
$70.58
Current Price
$18.58
$52.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Earnings expanding 20.6% YoY
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Moderate valuation
Smaller company, higher risk/reward
4.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PGNY
The strongest argument for PGNY centers on Altman Z-Score, Price/Book, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : PGNY
The primary concerns for PGNY are P/E Ratio, Market Cap, Profit Margin. Thin 4.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while PGNY is a value play — different risk/reward profiles.
PGNY carries more volatility with a beta of 0.99 — expect wider price swings.
PGNY is growing revenue faster at 6.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 50/100), backed by strong 23.9% margins. PGNY offers better value entry with a 69.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Progyny Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?